GoodRx reports that choosing the right asthma inhaler depends on symptom severity and frequency, with options for quick relief and daily control.

The arrival of spring in our area has brought warmer weather, blooming flowers, greener grass, and, for many, seasonal allergies. Seasonal allergies are caused by pollen produced by plants. Tree ...

The MostGraph impulse oscillation system may effectively assess airway resistance and resonant frequency in asthma and cough ...

The impact of pulmonary diseases on other chronic conditions is often misunderstood and commonly underreported. More than half the Americans with Chronic Obstructive Pulmonary Disease (COPD) have not ...

The experimental therapy tozorakimab from AstraZeneca was superior to a placebo at reducing the rate of moderate to severe exacerbations, or sudden episodes of symptom worsening, in adults with ...

Kymera Therapeutics (KYMR) stays a Strong Buy on KT-621 Phase 1b AD results, FDA Fast Track, and $1.6B cash runway—click to ...

More than 20 years after gaining FDA approval for Flovent, GSK still controlled the market in the U.S. for the asthma inhaler through a partnership with an “authorized generic” dealer, a setup that ...

Finally spring–and your dog suddenly shows signs of breathing difficulties? It could be asthma. While it’s less common in ...

Across the landscape of global biotech companies, the appointment of a senior executive often serves as a "barometer"-offering insights into a company's pipeline ...

Patients who received fluticasone furoate-vilanterol had a 9% lower risk for a first moderate or severe COPD exacerbation than those who received budesonide-formoterol (hazard ratio [HR], 0.91; 95% CI ...